Compare 10X Genomics Inc (TXG) vs Zillow Group Inc Class C (Z) Price & Performance

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Zillow Group (Z) trades at $27.28, down 1.52% on the day, with technical indicators signaling a bearish trend amid weak moving averages. The company reported revenue of $2.58 billion in 2025, with net income turning positive at $23 million, and recent quarters show mixed earnings performance with two beats and one miss. Analyst sentiment is divided, with a consensus price target of $60.33, while news highlights focus on market competition and AI integration in real estate.

The stock faces headwinds from a challenging housing market and high valuation multiples, but long-term growth potential exists through its transaction platform expansion and AI initiatives. Risks include interest rate sensitivity and competitive pressures, yet institutional analyst coverage remains largely neutral to positive, suggesting cautious optimism for recovery if execution improves.